Webinars & Online Seminars

What will be covered?

• RTK biology and drug discovery importance
• Tools needed to create your own RTK cell lines and assays
• Experimental design and workflows
• Applications of RTK and related cell-based assays

What will be covered?

• 世界で唯一：プライマリー細胞を使用した、ガンの微小細胞環境モデル
• 話題となっている免疫チェックポイント阻害剤の評価例
• 医療抗体の中でも低分子化合物が活躍？
• BioMAPシステムの応用例

What will be covered?

• The role of GPCRs in regulating host-microbial interactions
• How to identify microbial metabolites that modulate GPCR functions
• A case study on defining host-microbial interaction and therapeutic potential of N-acyl amides, bacterial metabolites that activate GPR132/G2A

What will be covered?

• Eliminating donor variability in cytotoxicity assays with single donor-derived primary human KILR CD16 Effector Cells
• Better analysis of antibody’s cytotoxicity profile with better Hill Slopes and higher S:B compared to PBMCs
• Faster assessment of redirected T cell-mediated cytotoxicity with rapid killing kinetics of the CD16 Effector cells

What will be covered?

• 全てのヒトのターゲットで安全性を確認
• 通常の結合データを上回る機能データ
• アッセイ開発のコストと時間を削減

What will be covered?

• Overview of compound-target engagement
• Tools and workflow to create your own cell-based target engagement assay
• Applications of InCELL Pulse assays

What will be covered?

• Using phenotypic profiling to characterize clinically successful drugs for a given indication
• Combining target-based and phenotypic data to prioritize drugs for repurposing
• Understanding how multi-targeted kinases can be pivoted towards new indications

What will be covered?

• Role of GPCRs in human cardiovascular system
• Strategies for exploiting orphan GPCRs recently paired with endogenous ligands illustrated by Apelin and Elabela/Toddler
• Identifying biased agonists using pharmacologically-relevant functional cell based assays
• Validating assays and minimizing inter-assay variation

What will be covered?

• Overview of compound-target engagement and InCELL Pulse platform
• Kinase drug discovery importance
• Tools and workflow needed to create your own target engagement assay
• Validation data showing several examples of diverse kinases

What will be covered?

• 抗腫瘍免疫応答が増強に活用される免疫チェックポイント阻害剤の評価系
• PD-1, PD-L1, PD-L2, TWEAK, CD40, OX40, VISTA などの実施例
• 放射性同位体を使用しないADCC（抗体依存性細胞傷害）の評価系

What will be covered?

• Overview of the mu opioid receptor signaling
• GPCR splicing, using OPRM1 as an example
• Region and cell specific splicing
• Functional consequences of 5’ splicing
• Functional consequences of 3’ splicing

What will be covered?

• Opportunities and challenges for targeting GPCRs in oncology
• Examples of GPCR-targeting investigational therapies for oncology
• Imipridones, selective GPCR-targeting small molecules, that are in preclinical and clinical development for oncology

What will be covered?

• Learn about the significance of kinase broad profiling and phenotypic screening on early kinase drug discovery
• Learn how to design a kinase inhibitor broad profiling project and how the chemo-bioinformatic analysis can impact target deconvolution after phenotypic screening

What will be covered?

• Overview of compound-target engagement
• Tools needed to create your own target engagement assay
• Experimental design and workflow
• Applications of InCELL Pulse assays

What will be covered?

• Screening approaches for GPCR drug discovery
• Creating a duplexed assay to monitor calcium and β-arrestin in a single well

• Determine potential bias for various drugs and define potency ranking

What will be covered?

• Challenges in immuno-oncology drug development
• Tools to expedite and simplify any immuno-oncology drug development pipeline

What will be covered?

• Overview of the BioMAP® immuno-oncology/oncology systems
• Information BioMAP iOnc studies provide
• Host stromal/vascular - tumor microenvironment biology
• Case studies of profiling Ab therapies (anti-PD-1, anti-CTLA-4, etc.) and preclinical compounds

What will be covered?

• 2016の創薬市場：「スマート」になった現在の薬剤
• チェックポイント阻害剤の評価系・インターロイキン受容体・GPCR等
• キナーゼ阻害剤・エピジェネティック阻害剤・PPI創薬のスクリーニング
• 候補薬剤の表現型プロファイリング

What will be covered?

• Overview of the BioMAP Diversity PLUS phenotypic screening platform's modeling of broad human tissue and disease biology
• Details of how Diversity PLUS profiling guides new indications for marketed drugs and pre-clinical candidates
• Examples highlighting how this technology is used to support repositioning of approved drugs for alternate indications

What will be covered?

• How PathHunter^® GPCR Screening and Profiling Services can be used to triage hits, rank order compounds, and develop novel biased ligands
• Tools to understand the mechanism of action of your drugs and their mode of action
• How a case study of clinically approved drugs in our broad range of GPCR assays can be used to predict the selectivity and safety of your drug candidates

What will be covered?

• Overview of the KINOMEscan assay technology
• Application of the KINOMEscan platform for selectivity and potency optimization
• Development of chemical probes for understudied kinases

What will be covered?

• Novel cell-based assays for checkpoint signaling receptors
• Functional assays for biologics and small molecule screening
• Applications for QC lot release testing of biologics
• Assays for CD137, CTLA-4, TIGIT, PD-1, OX-40, CD40, TWEAK, TIM3, and VISTA
• Custom assay development for novel checkpoint targets

What will be covered?

• KINOMEscanアッセイ原理の詳細：結合系と機能系を比較
• 新規キナーゼ標的：CDK10, CDK12, CDK20, MLKL and MLKL (full length), IRAK2 等
• 40種類ものブロモドメインに対する阻害剤を評価
• アポトーシス阻害剤の同定：BCL2scan
• scanMAX報告書から得られる、裏データ・裏情報のご紹介

What will be covered?

• Overview of β-arrestin biology
• Tools needed to create your own β-arrestin cell lines and assays
• Experimental design and workflows
• Applications of β-arrestin cell-based assays for GPCRs

What will be covered?

• Simple cell-based assays to measure target cell cytotoxicity in a co-culture
• Assays for ADCC, ADCP, bi-specific antibody mediated T-cell redirection, and adoptive T-cell therapies such as CAR-T
• Enabling technology to drive a cancer immunotherapy drug through the discovery and development pipeline

What will be covered?

• How to maximize knowledge of your compounds using the BioMAP^® Diversity PLUS™ panel of human primary cells systems
• How to understand mechanism classification analysis and toxicity signatures
• A case study on discovery of a mechanism-based novel signature for skin irritation

What will be covered?

• Creation of cell-based bioassays for potency and stability testing
• Application, development and validation of assays with drug molecule
• Case studies on Avastin (bevacizumab), Eylea (aflibercept) and Lucentis (ranibizumab)
• Qualified assays for > 30 biosimilars

What will be covered?

• Capabilities overview of LeadHunter Discovery Services
• Identifying, characterizing and quantifying novel biased ligands using LeadHunter Services

• Multiple pathways including ß-Arrestin and how biased signaling can influence efficacy in vivo

What will be covered?

• Tofacitinibの様な抗炎症剤から、食材までの表現型解析例の紹介
• 臨床試験への架け橋となったデータの実施例
• Skin Rash・Thrombosis等を明瞭に：BioMAPシステムの応用例
• パワーアップした試験報告書のご紹介：さらに充実したデータのご提供
• メカニズム探査によるリード化合物の毒性、薬理、安全性等の同定

What will be covered?

• Overview of membrane protein trafficking and protein misfolding diseases
• Assay technology to simplify monitoring of protein trafficking
• Screening for pharmacological chaperones

What will be covered?

• Simple cell-based assays for checkpoint signaling receptors
• Assays with human primary cells in co-culture recreating the human tumor microenvironment

• Enabling technologies to move an immune-oncology drug along the discovery and development pipeline
• Drugs targeting PD-1, PD-L1, PD-L2, TWEAK, CD40, OX40, and VISTA, among others

What will be covered?

• 抗腫瘍免疫応答が増強に活用される免疫チェックポイント阻害剤の評価系
• PD-1, PD-L1, PD-L2, TWEAK, CD40, OX40, VISTA　などの実施例
• 放射性同位体を使用しないADCC（抗体依存性細胞傷害）の評価系

What will be covered?

• Application of KINOMEscan technology for selectivity and potency optimization of your lead molecules
• Design scanMAX, KdELECT or scanELECT experiments
• Improved flexibility of custom panels for hit identification, hit to lead, SAR and lead optimization
• 20 new kinase assays launched in 2016

What will be covered?

• Novel cell-based assays for checkpoint signaling receptors
• PD-1, PD-L1, PD-L2, TWEAK, CD40, OX40, and VISTA, among others
• Functional assays for biologics and small molecule screening
• Applications for QC lot release testing of biologics

What will be covered

• Capabilities overview of LeadHunter Discovery Services
• How LeadHunter can be used to identify, characterize and quantify novel biased ligands
• Discover how multiple pathways including ß-Arrestin can influence efficacy in vivo